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RESUMO 
A doença de Parkinson é a segunda doença neurodegenerativa mais comum, 
afectando 1% da população acima dos 55 anos de idade [5]. A agregação da proteína 
α-sinucleína tem sido associada à sua etiologia. Em termos patológicos a doença de 
Parkinson é caracterizada pela perda progressiva de neurónios dopaminérgicos 
nigrostriatais e a presença de inclusões de proteína predominantemente compostas 
por α-sinucleína fibrilar, denominados corpos de Lewy, em neurónios dopaminérgicos. 
Apesar de os tratamentos atuais poderem melhorar os sintomas da doença de 
Parkinson, não há terapias disponíveis que retardem ou parem a progressão da 
doença. Desde 1997, quando foi descoberto que uma mutação missense no gene da 
α-sinucleína causa a forma familiar desta doença, o papel da α-sinucleína na etiologia 
e patologia tem sido extensivamente estudado. O desenvolvimento e caracterização 
de modelos animais baseados na α-sinucleína são passos cruciais para compreender 
a patogénese da doença, bem como para fornecer uma estrutura para testar 
estratégias terapêuticas. Neste estudo, e com o objectivo de estudar a propagação da 
patologia da doença de Parkinson, co-injectamos vírus adeno-associados que 
codificam α-sinucleína combinada com o N- ou C-terminal da proteína fluorescente 
Vénus em regiões do cérebro de ratos afectados na doença de Parkinson, tais como o 
córtex motor (Grupo CX), corpo estriado (Grupo ST) e na substantia nigra (Grupo SN) 
e descrevemos um novo modelo roedor basedo num vector viral com a capacidade de 
detetar e rastrear a agregação de α-sinucleína in vivo. Para este efeito, foi utilizada a 
técnica de complementação de fluorescência bimolecular. A co-injecção viral resultou 
em sinal Venus difundido na via corticoespinhal (Grupo CX) e na via nigroestriatal 
(Grupo ST e SN), incluindo nos corpos celulares nos locais de injecção e acumulação 
sináptica, sugestiva da formação de oligómeros de α-sinucleína. Os animais injectados 
com α-sinucleína apresentaram inchaços axonais. No entanto, não houve perda 
significativa de neurónios na substantia nigra do Grupo SN e nem perda significativa 
de terminais nervosos no corpo estriado do Grupo SN e ST. De acordo com estes 
resultados, ambos os grupos também não apresentaram nenhum comprometimento 
comportamental ou sinais de neuroinflamação. Desenvolvemos um modelo animal que 
fornece uma ferramenta para a pesquisa da doença de Parkinson, permitindo a 
deteção direta de oligómeros de α-sinucleína in vivo e consequentemente, o 
conhecimento que advirá, será essencial para o estudo desta patologia assim como 
para o desenvolvimento de novas estratégias terapêuticas para a intervenção na 
doença de Parkinson. 
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ABSTRACT 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease, affecting 1% of the population over 55 years of age [5]. Alpha synuclein (α-
Syn) aggregation has been closely linked to its aetiology. Pathologically PD is 
characterized by the progressive loss of nigrostriatal dopaminergic neurons and the 
presence of protein inclusions predominantly composed of fibrillar α-Syn termed Lewy 
bodies within dopaminergic neurons. Although current treatments can ameliorate the 
symptoms of PD, there are no available therapies that would slow-down or stop the 
progression of the disease. Since 1997, when it was discovered that a missense 
mutation in the gene for α-Syn caused familial PD, the role of α-Syn in the aetiology 
and pathology has been extensively studied. Development and characterization of α-
Syn-based animal models are crucial steps to understand pathogenesis of the disease, 
as well as to provide a framework to test therapeutic strategies. Here, and with the 
main goal of study the Parkinson pathology propagation, we coinjected adeno-
associated virus (AAV) vectors encoding α-Syn fused to either the N- or C-terminal of 
Venus in rat brain areas affected in PD such as motor cortex (CX group), striatum (ST 
group) or substantia nigra (SN group) and describe a novel viral vector rodent model 
with the ability to directly detect and track α-Syn aggregation in vivo. For this purpose 
we used the bimolecular fluorescence complementation (BiFC) assay. Viral coinjection 
resulted in widespread Venus signal within the corticospinal tract (CX group) and within 
the nigrostriatal pathway (ST and SN groups) including cell bodies in the injection sites 
and synaptic accumulation, suggestive of α-Syn oligomers formation. Transduced rats 
showed axonal swellings. However, there was no significant neuron loss in the 
substantia nigra of SN group and no significant loss of nerve terminals in the stiatum of 
SN and ST group. Concordant with this, both groups also did not exhibit any 
behavioural impairment or signs of neuroinflammation. We have developed an animal 
model that provides a tool for Parkinson’s disease research allowing the direct 
detection of α-Syn oligomers in vivo and ultimately, the knowledge coming from it will 
be essential for the study of this pathology as well as for the development of novel 
therapeutic strategies for intervention in PD. 
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V1S - pAAV2-Venus1NPart-linker-hSyn-WPRE 
WPRE – woodchuck hepatitis virus post-transcriptional regulatory element 
WT – wild type 
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Chapter 1. INTRODUCTION 
 Parkinson`s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that was 
originally described by James Parkinson in 1817 [6]. It is the second most common 
neurodegenerative disease, aﬀecting 1% of the population over 55 years of age[5]. PD 
belongs to a family of diseases called synucleinopathies, which also includes dementia 
with Lewy bodies (DLB) and PD with dementia (PDD) [7]. Synucleinopathies are 
neurological disorders, which although differing significantly in their symptomatic 
presentation, have in common α-synuclein (α-Syn) aggregation and neuronal 
degeneration [8, 9].  Bradykinesia, resting tremor, rigidity, and postural instability are 
the major characteristic motor symptoms of PD. The nigrostriatal pathway is the one 
mainly affected in PD giving rise to the motor symptoms, since it is the main 
dopaminergic pathway in the brain which accounts for ~75% of the dopamine in the 
brain [39] being involved in the coordination of movement. There have been reports of 
an early impairment in olfactory function, before occurrence of the motor symptoms in 
PD [10, 11]. In addition, many patients with PD have a loss of sympathetic innervation 
to the heart giving rise to cardiac dysfunction [12]; gastrointestinal disturbance, such as 
constipation, are a common early symptom [13]. As the disease progresses, other non-
motor symptoms such as cognitive deficits and depression often occur [14, 15]. Other 
non-motor symptoms include sleep disorders, fatigue, psychosis and sexual 
dysfunction [16, 17]. (Fig.:1.1) 
 
Parkinson’s Disease: A sporadic and familial disease  
There are two major forms of PD: idiopathic (sporadic) and hereditary (familial). 
Most PD cases are idiopathic, with unknown genetic component. Only about 5–10% of 
PD patients have familial patterns of inheritance [18]. A direct genetic connection 
between α-Syn and PD has been established by evidence that three missense point 
mutations (A30P [19], E46K [20], and A53T [21]) and multiplications of the gene locus 
(non A4 component of amyloid precursor) (SNCA), which encodes α-Syn, underlie 
autosomal dominant forms of PD [22].  Importantly, genome-wide association studies 
have shown clearly that SNCA is also linked to sporadic  PD [23]. The aggregation of 
α-Syn into fibrillar assemblies in nerve cells is a molecular hallmark of the disease [24]. 
Unfolded monomers interact to form unstable dimmers, which grow slowly to generate 
oligomers of different morphologies that eventually convert to fibrils [2]. Moreover α-
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Syn is found aggregated in Lewy bodies (LB) and Lewy neurites (LN) in both familial 
and idiopathic cases of PD. LB appear as cytoplasmic inclusions while LN correspond 
to abnormal neurites that contain filaments similar to those found in LB [8].  
 
 
The etiology of the idiopathic PD remains unknown so far. Aging is the major 
risk factor linked to the development of the disease but a combination of lifestyle, 
environmental and genetic factors have also been implicated. Epidemiological studies 
had also revealed several risk factors for developing idiopathic PD, including exposure 
to pesticides, herbicides, and some industrial chemicals [25]. 
In sporadic cases of PD, increased levels of α-Syn might be a consequence of 
impaired clearance of the protein. α-Syn is normally cleaned by the 
autophagy/lysosomal and ubiquitin proteasome systems [26-30], and defects in these 
systems have been detected in patients with sporadic PD [31, 32]. Elevated oxidative 
Fig.: 1.1 - Representative schematization of the Symptomatology of Parkinson’s Disease. (Adapted from 
“3DScience”) 
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and metabolic stresses are thought to contribute to the pathogenesis [33]. Impaired 
mitochondrial complex I can cause an increase on the concentration of reactive oxygen 
species, which can accelerate α-Syn aggregation [34, 35]. An impaired ubiquitin-
proteasome degradation system may also play a role in initiating PD pathogenesis [33]. 
Increased misfolding of proteins due to oxidative damage could overwhelm and inhibit 
the proteasome degradation machinery. At the end, inefficient degradation may cause 
the accumulation of α-Syn and, by elevating α-Syn concentration, there is an increase 
in the rate of α-Syn aggregation [29]. 
 
 
 
 
The major neuropathological hallmarks of PD are degeneration and cell death 
of dopaminergic neurons [9]. On a cellular level, PD is characterized by the formation 
and accumulation of proteinaceous intraneuronal inclusions, known as LB, in the 
perikarya, dendrites, and axons of dopaminergic nerve cells in the substantia nigra 
pars compacta (SNpc) as well as other regions of the central and peripheral autonomic 
nervous systems [36, 37]. (Fig.:1.2) LBs consist of a granular core that includes a wide 
variety of nitrated, phosphorylated, and ubiquitinated proteins surrounded by a 
ﬁlamentous halo primarily comprised of neuroﬁlaments and α-Syn [36]. While initially 
thought to be toxic and contribute to neurodegeneration, LB might in fact represent a 
form of aggregosome that develops in response to increased levels of misfolded 
proteins to segregate and facilitate the clearance of these potentially toxic proteins [38]. 
Fig.: 1.2 - Brain regions affected in Parkinson’s disease and Lewy Bodies in PD  human brain tissue. 
Immunohistochemistry for α-Syn (right) shows the presence of LBs in the SN. (Adapted from “Diseasespictures”) 
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However, identification of the toxic α-Syn species is still a matter of intense 
investigation in the scientific community. 
α-Synuclein structure, function and localization 
α-Syn is an abundant and highly conserved neuronal protein of 140 aminoacids 
that, under physiological conditions, is found mainly in neuronal presynaptic terminals 
in proximity to synaptic vesicles. It is a member of a conserved family of proteins that 
also includes β-synuclein and γ-synuclein, and was originally described as the 
precursor protein for the non-amyloid component of Alzheimer’s disease senile plaques 
[39].  
α-Syn is constituted by a positively charged N-
terminal region (residues 1-60), a hydrophobic NAC 
region (residues 61-95) and a negatively charged C-
terminal region (residues 96-140). (Fig.:1.3) The N-
terminal half of α-Syn contains seven 11-amino acid 
repeats with a highly conserved motif KTKEGV. This 
domain is responsible for protein-protein interactions 
(PPIs) and for forming structural apolipoprotein-like class 
A2 amphipathic α-helical by binding of α-Syn to 
phospholipid vesicles [40]. The central hydrophobic NAC 
region of α-Syn is highly amyloidogenic and this confers the capacity to undergo a 
conformational change from random coil to β-sheet structure, protofibrils and fibrils. 
The acidic C-terminal region remains unfolded and does not associate with vesicles. 
This region contains serine 129 (S129) and tyrosine 125 (Y125) residues that can play 
a role in α-Syn fibrillization [41]. 
The protein is intrinsically unfolded, which means that in the puriﬁed form at 
neutral pH it lacks an ordered secondary or tertiary structure. Upon binding to 
membranes or synthetic vesicles containing acidic phospholipids, however, it assumes 
an α-helical structure [42]. α-Syn oligomers are known to bind and permeabilize 
vesicles composed of negatively charged lipids [41]. 
Recombinant α-Syn incubated under certain conditions in vitro assumes an 
oligomeric conformation and is gradually converted to β-sheet-rich, ﬁbrillar structures 
that resemble the LB and neurites found in human neuropathological samples. This 
process is termed aggregation and is thought to underlie the toxic potential of α-Syn 
[42].  
Fig.: 1.3 – α-Syn structure and 
domains. (Adapted from Lashuel  et 
al . 2013 {Lashuel , 2013 [2])  
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Although the precise functions of α-Syn remain uncertain, the preferential 
localization to presynaptic nerve terminals and its interaction with phospholipids and 
proteins suggests regulatory functions associated with synaptic activity, dopamine 
metabolism and lipid vesicle trafficking [40, 43-48], having a stabilising effect on 
complexes of soluble NSF(N-ethylmaleimide-sensitive factor) attachment protein 
receptor (SNARE) family proteins [49-52]. (Fig.:1.4) The stabilising effect of α-Syn on 
the SNARE-complex assembly is made by a non-enzymatic mechanism that involves 
simultaneous binding of α-Syn to phospholipids via its N-terminus, and to 
synaptobrevin-2 via its C-terminus [46]. 
Relative loss of α-Syn function, for example by sequestration of α-Syn in LB or 
by increased truncation of α-Syn during aging, may thus contribute to 
neurodegenerative diseases such as PD and LBD. 
 
 
 
 
Fig.: 1.4 - Function of α-Synuclein. α-Syn has key role in the regulation of neurotransmitter release, synaptic 
function and plastici ty. At the pre -synaptic terminal  i t exerts  its  function in the regulation of vesicle trafficking and 
vesicle refilling, besides interactions  between target-associated SNARE and vesicle - associated SNARE proteins  and 
neurotransmitter release. In case of accumulation of α-Syn, occurs  an impairment of these mechanisms. (Adapted 
from Irwin.DJ,. et al ., 2013 [2]) 
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α-Synuclein in PD (and other synucleinopathies) 
The molecular mechanisms by which α-Syn aggregation contributes to 
neurodegeneration, the nature of the toxic forms of α-Syn and the cellular pathways 
that are affected by α-Syn remain unknown. An increasing body of evidence from 
animal models as well as data from genetic, biochemical and biophysical studies 
sustain the hypothesis that the processes of α-Syn oligomerization [53], and fibril 
growth [54, 55] have central roles in the pathogenesis of PD and other 
synucleinopathies [56]. In addition, it is possible that the α-Syn monomers might also 
have a role in synucleinopathies by their displacement from their physiological location, 
resulting in a loss of cellular function, or by disrupting the activity of other molecular or 
signalling pathways [57].  
There are a number of different α-Syn conformers, including oligomers, 
protofibrils and fibrils, which have been associated with the pathogenesis [58, 59]. The 
fibrillar forms of α-Syn are detected mostly in LB [53, 60, 61] and are thought to reflect 
an attempt by the neurons to isolate and/or convert toxic α-Syn oligomers to fibrils, 
which are stable, less dynamic structures that exhibit reduced toxicity. In contrast to 
fibrillar α-Syn, oligomeric aggregates are most likely to be located in axons and 
presynaptic terminals, where they might damage synapses and dendrites [58, 62-66], 
and destabilize cytoskeletal units which in turn might accelerate the formation of α-Syn 
oligomers and further cytoskeletal disruption resulting in neuritic degeneration [39]. 
Spherical oligomers 2–6 nm in diameter may be the toxic forms of α-Syn, as they 
promote abnormal calcium currents and neuronal degeneration in cultured primary 
neurons [67]. There is still the possibility that α-Syn oligomerization may alter the 
distribution of functional forms of monomeric α-Syn or result in sequestration into non-
functional oligomeric forms, thus resulting in partial loss of α-Syn function [68]. Or even, 
the native or misfolded forms of the monomeric protein may contribute to α-Syn toxicity 
and PD pathogenesis via aggregation‑independent mechanisms, including aberrant 
interactions with membranes, proteins and small molecules, retention in specific 
cellular compartments, and disruption of specific cellular processes. (Fig.:1.5) 
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Fig.: 1.5 - Mechanisms of α-Synuclein aggregation, propagation and clearance.  α-Syn aggregation can occur in the 
cytoplasm or with the cellular membrane. In the cytosol , unfolded monomers  form dimers , which grow to generate 
oligomers  — including transient spherical and ring-like oligomers — that convert to fibrils . The accumulation of amyloid 
fibrils leads to the formation of Lewy bodies. Membrane -bound monomeric α-Syn adopts  a mostly α-helical 
conformation, but at high concentrations i t undergoes a  conformational  change to form membrane-bound β-sheet-rich 
s tructures  that form oligomers . During α-Syn fibrillogenesis  and aggregation, the intermediate species  (oligomers  and 
amyloid fibrils) are highly toxic, affecting mitochondrial function, endoplasmic reticulum-Golgi trafficking, protein 
degradation and/or synaptic transmission, inducing neurodegeneration. Quality-control  systems (chaperones, ubiquitin 
proteosomes and phagosome-lysosome systems) that prevent or reverse protein misfolding or eliminate misfolded 
proteins are overwhelmed by oligomeric species of α-Syn. α-Syn oligomers and fibrils , as well as the monomers , can be 
transferred between cells and induce disease dissemination to other brain regions . Spreading mechanisms  can occur 
via  endocytosis, di rect penetration, trans-synaptic transmission or membrane receptors . Once inside the host cells, α-
Syn aggregates  can nucleate aggregation and propagate. (Adapted from Irwin, D.J., et al., 2013 and Lashuel , HA., et al ., 
2013  [2, 3]) 
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Toxicity of particular α-Syn species has been debated but not yet resolved in a 
satisfactory manner. In any case the levels of α-Syn in the central nervous system 
(CNS) depend on the balance between the rates of α-Syn synthesis, aggregation and 
clearance. The ubiquitin proteasome system and the autophagy-lysosome pathway, 
(which involves microautophagy, macroautophagy, and chaperone-mediated 
autophagy) are the two major quality-control systems postmitotic neurons use to 
maintain intracellular proteostasis [69]. An imbalance between these mechanisms, 
caused by dysfunction of one or more of these pathways, can result in abnormal levels 
of α-Syn that might favour the formation and/or accumulation of oligomeric and fibrillar 
species. (Fig.:1.5) Whether accumulation of α-Syn precedes the impairment of 
autophagic pathways or vice versa remains as well unclear [39]. Damage to 
proteasomal and lysosomal systems could cause α-Syn to accumulate, as well as the 
increased levels of α-Syn could inhibit the proteasome and lysosomal systems, 
ultimately leading to the formation of oligomers and aggregates with resulted 
neurodegeneration and clinical dysfunction [70]. Additionally α-Syn might suffer a 
conformational transition from an α-helix–rich structure to one high in β-sheet structure. 
If such a stochastic process were to escape physiological control by the protein 
clearance systems, this could result in increased levels of misfolded protein, which 
could then act as a template to promote misfolding of native wild type α-Syn and a 
prion-like chain reaction leading to neurodegeneration [36]. 
Protein post-translational modifications are fairly significant in the regulation of 
the protein structure and function. These modifications result in alterations in protein 
size, structure, charge, and folding, which may interfere with their activity, binding 
affinity and hydrophobicity of proteins [71]. Protein phosphorylation is the most studied 
and considered the most important post-translational modification. Data from 
immunohistochemical and biochemical studies demonstrated that most of α-Syn within 
LB, isolated from PD patients and others synucleinopathies, is phosphorylated at 
Serine 129 (S129). Protein phosphorilation of α-Syn at S129 is believed to be 
intrinsically linked to PD pathogenesis [72-74].  In addition, the detection of 
phosphorylated S129 has been one of the key criteria to identify LB in human brains as 
well as in animal models [72, 74]. Phosphorylation play a role in modulation of α-Syn 
aggregation, LB formation and toxicity in vivo [73]. 
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Prion-like hypothesis of spread of pathology in PD 
Recent studies highlighted possible similarities in mechanisms underlying the 
propagation of α-Syn with that of prions [75, 76]. The fundamental event in the biology 
of a prion is a conformational transition that converts the normal cellular protein to a 
misfolded isoform. These, in turn, polymerize into oligomers and amyloid ﬁbrils that 
coalesce into plaques and cause neurodegeneration [36, 77]. 
Under physiological conditions, α-Syn has been traditionally considered to be 
an exclusively intracellular synaptic protein. However, evidence suggests that under 
pathological circumstances, toxic α-Syn oligomers could be eliminated from neurons 
via unconventional secretory mechanisms [78-80]. 
Abnormal deposition of α-Syn occurs early in the disease process, and seems 
to follow a sequence of ascension from lower brainstem centres to limbic and wide 
cortical association areas [81]. LB pathology propagates in a sequential and 
predictable fashion, beginning in the olfactory system, peripheral autonomic nervous 
system, and dorsal motor nucleus of the vagus; extending to involve dopamine neurons 
of the SNpc in the mid stage of the disease; and affecting the cerebral hemispheres in 
the later stages of the illness [82]. (Fig.:1.6)  Lewy pathology affects norepinephrine 
neurons of the locus coeruleus, cholinergic neurons of the nucleus basalis of Meynert, 
serotonin neurons of the median raphe, and speciﬁc sets of nerve cells in the olfactory 
system, neocortex of the cerebral hemispheres, upper and lower brainstem, spinal 
cord, and peripheral autonomic nervous system [83]. It has been hypothesised that this 
pathology can be initiated and propagated by an unknown pathogen, aggregated form 
of α-Syn being the major candidate [4, 36].  
Fig.:1. 6 – Lewy Body pathology propagation. The ﬁrst lesions  appear in the olfactory bulb, anterior ol factory 
nucleus, and dorsal motor nucleus  of the vagus nerve. From there, the pathology follows a  p redominantly ascending 
path affecting the locus  coeruleus , gigantocellular reticular nucleus , and caudal raphe nuclei .  The pathology 
continues  i ts  ascent and reaches  the central  subnucleus  of the amgygdala, the cholinergic nuclei  of the basal 
forebrain, a nd the pars  compacta  of the substantia nigra . The cerebral  cortex becomes  involved in a  later s tage, 
commencing with the anteromedial temporal mesocortex.  The higher order association areas of the neocortex 
become involved later, followed by the ﬁrst-order association areas and primary ﬁelds . Growing severi ty of the 
lesions is shown by increasing degrees of shading (red, violet, black (Adapted from Braak, H., et al ., 2003) [4] 
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There is also an increasing body of evidence showing the transfer of α-Syn between 
cells and propagation of the disease both in vitro and in vivo. In vitro studies 
demonstrate that α-Syn monomers and aggregates can be secreted from affected 
neurons via exocytosis and taken up by unaffected neurons via endocytosis [84, 85]. 
Brains from PD subjects transplanted with fetal mesacenphalic dopaminergic neurons 
exhibit that the disease can propagate from host brain to grafted cells [86]. 
Pathways leading to the release of toxic α-Syn oligomers include exocytosis in 
clear vesicles [85], exosomal release [79, 87], and penetration [88, 89]  from the donor 
cell membrane. Interestingly, these extracellular α-Syn aggregates can then transfer 
from neuron to neuron or from neuron to glial cell [85], where they can nucleate further 
intracellular aggregation and/or trigger neuroinflammation to exacerbate the 
neurodegenerative process [90, 91].  
The mechanisms through which extracellular α-Syn oligomers transfer to other 
cells include endocytosis [92], direct penetration [93], trans-synaptic dissemination [79] 
and membrane-receptor-mediated access [85]. (Fig.: 1.6) Once inside the recipient 
cells, α-Syn oligomers could act as a seed for intracellular aggregation or the protein 
could be targeted for degradation. Although the exact process of intracellular oligomer 
and fibril propagation remains unknown, evidence from in vitro biophysical studies has 
consistently shown that fibrillization of α-Syn follows a nucleated polymerization 
mechanism [94]. Moreover an in vivo study has shown that inoculation of α-Syn 
transgenic mice with homogenates containing α-Syn protofibrils and fibrils results in 
enhancement of the α-Syn pathology and propagation [95]. These observations led 
once more to the hypothesis that extracellular α-Syn seeds might behave in a prion-like 
fashion.  
 
Basal ganglia 
The basal ganglia consist of a set of brain structures in the telencephalon, 
diencephalon, and mesencephalon. The forebrain structures comprise the caudate 
nucleus, the putamen, the nucleus accumbens (or ventral striatum) and the globus 
pallidus. Collectively, these structures are named the corpus striatum. The subthalamic 
nucleus is part of the diencephalon and it is placed under the thalamus. The substantia 
nigra is a midbrain structure, composed of two parts: the pars compacta (SNpc) and 
the pars reticulata (SNpr). The substantia nigra is sited between the red nucleus and 
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the cerebral peduncle on the ventral part of the midbrain. The pars compacta is the 
source of a dopaminergic pathway to the striatum. [96, 97] 
The striatum is the major receiver of afferents to the basal ganglia [98]. These 
excitatory afferents arise from all cerebral cortex and from the intralaminar nuclei of the 
thalamus. The main output structures of the basal ganglia are the globus 
pallidus internal segment (GPint) and the SNpr. Both of these structures make 
GABAergic, inhibitory connections on their targets.  
An essential pathway in the modulation of the direct and indirect pathways is 
the dopaminergic, nigrostriatal projection from the SNpc to the striatum. Direct pathway 
striatal neurons have D1 dopamine (DA) receptors, which depolarize the cell in 
response to DA. On the contrary, indirect pathway striatal neurons have D2 DA 
receptors, which hyperpolarize the cell in response to DA. The nigrostriatal pathway 
has the dual effect of exciting the direct pathway while inhibiting the indirect pathway. 
Because of this dual effect, excitation of the nigrostriatal pathway leads to the 
excitation of cortex by two routes, by exciting the direct pathway and inhibiting the 
indirect pathway.  
The neurodegeneration in the nigrostriatal pathway results in the motor 
symptoms in PD [99]. Since the nigrostriatal pathway is both excitatory and inhibitory, 
the loss of this input tips the balance in benefit of activity in the indirect pathway. 
Therefore, the GPint neurons are abnormally active, maintaining the thalamic neurons 
inhibited. Without the thalamic input, the motor cortex neurons are not as much excited, 
and consequently the motor system lags behind to execute the motor plans in 
response to the patient’s volition.  
 
Animal models of PD 
Development of relevant animal models of PD is crucial for elucidating the 
etiopathology of the disease as well as for evaluation of potential therapeutic targets.  
Several animal models are currently used; however, there are certain drawbacks in 
each particular model. A model representing all the PD hallmarks together with 
consistent symptomatology is still lacking. 
The development and characterization of α-Syn-based animal models might 
bring important insights into PD-linked pathology [100]. There are several models, 
being the genetic and toxin-induced ones the most used. Numerous α-Syn-based 
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models including toxin-induced animal models, being in use in primates and rodents 
have been developed and characterized. Although these models can bring valuable 
insights into the disease pathology processes, they present several drawbacks. More 
recently, adeno associated virus (AAV)-based models were developed and, compared 
to the previous models they bring some advantages. 
Neurotoxin Models  
6-hydroxydopamine (6-OHDA) induced model of PD was first used in 1968 [101]. 
Injection of this toxin in the SNpc results in about  60%  tyrosine hydroxilase (TH)-
neurons cell loss in the midbrain dopaminergic system, with subsequent loss of TH-
positive terminals in the striatum [102], however 6-OHDA does not produce or induce 
proteinaceous aggregates or Lewy-like inclusions like those seen in PD. 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is used in primates [69] and mice 
[103], however cannot be used in rats since they are found to be resistant to this toxin 
[104]. It replicates almost all of the hallmarks of PD in monkeys, however it does not 
induce formation of LB [105]. 
 
Pesticide/herbicide Models 
Paraquat (N,N-dimethyl- 4–4–4-bipiridinium)  is a herbicide. It induces its effects 
throughout oxidative stress mediated by redox cycling, which in turn generates reactive 
oxygen species that result in the damage of lipids, proteins, DNA and RNA. It leads to 
an increase in α-Syn and presence of LB in DA neurons of the SNpc [105, 106]. 
Rotenone is both an herbicide and an insecticide. It seems to replicate almost all of the 
hallmarks of PD including complex I blockade, behavioural alterations, inﬂammation, α-
Syn aggregation, Lewy-like body formation, oxidative stress and gastrointestinal 
problems [107]. However, it does not cause major depletion of DA in the nigrostriatal 
system [108]. 
 
Genetic Models 
Although genetic mutations in PD are rare and represent only about 10% of all 
PD cases [1], animal models of these mutations [α-Syn and LRRK2 (leucine rich repeat 
kinase 2), autosomal dominant PD, and PINK1 (phosphatase- induced novel kinase 
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1)/Parkin and DJ-1, autosomal recessive PD] are important as they represent potential 
therapeutic targets. Moreover, in the case of α-Syn there is evidence from genome-
wide association study linking variations in SNCA gene with higher risk of PD [109, 
110] and it is also known that aggregation of α-Syn is present in sporadic PD [61]. 
Nowadays, there are several transgenic mouse models, for the wild type or the 
mutated α-Syn, under promoters strictly neuronal or not strictly neuronal. In 2000 the 
first α-Syn knockout mice was created [111].  In 2002  it was shown for the first time 
that α-Syn knockout mice exhibits DA neuron loss in the presence of MPTP [112]. In 
2000 Masliah and co-workers developed the first α-Syn transgenic mice, using a 
platelet derived growth factor (PDGFβ) promoter [113]. One year later the [A53T] α-Syn 
[114] and [A30P] α-Syn [115] transgenic mouse models were created. Up to date [wt] 
α-Syn or a double-transgenic [A53T, A30P] α-Syn mouse models are also available for 
the study of PD [116]. 
Most of the rat models of PD have been developed based on the connection 
between α-Syn and PD. However the first PD rat models employed neurotoxins such 
as 6-OHDA or MPTP, that acutely degenerate DA neurons in substantia nigra but don 
not outcome a significant α-Syn pathology [101]. Models using viral vectors to target α-
Syn expression in the substantia nigra were recently developed. Those α-Syn-
overexpressing rat models show neuronal loss and LB inclusion formation [100]. 
Overexpression of α-Syn in transgenic rodents can lead to loss of nigral 
dopaminergic neurons and the accumulation of α-Syn aggregates [113]. Finally, 
overexpression of α-Syn via gene delivery to the region of the SNpc leads to the 
formation of inclusion bodies immuno-positive for α-Syn, degeneration of dopamine 
neurons, and parkinsonian motor disturbances in both rats and monkeys [117]. Those 
results, with accompanied dopaminergic cell loss, resemble more closely the chronic 
pathology of PD [118-121]. 
Despite all the advantages of these models, the detection of α-Syn oligomers is 
based on indirect approaches, without the possibility of direct in vivo detection. 
Recently a new rat PD model,  which enabled the direct detection and visualization of 
α-Syn oligomers along the nigrostriatal pathway by using bimolecular fluorescence 
complementation assay (BiFC), was presented [122]. BiFC assay is based on the 
chemiluminescence signal from fluorescent protein conjugates which enable the 
detection and imaging of α-Syn oligomers in vivo. 
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Bimolecular fluorescence complementation (BiFC) 
Protein-protein interactions (PPIs) play significant roles in various biological 
processes. To study PPIs, several methods, such as canonical yeast two-hybrid assay, 
in vitro pull-down assay, in vivo immunoprecipitation assay, fluorescence resonance 
energy transfer  (FRET) assay, bioluminescence resonance energy transfer (BRET) 
assay, and BiFC assay, have been used [123].  
 
 
 
 
 
Over the past decade, BiFC has emerged as a key technique to visualize PPIs 
in a variety of model organisms. The BiFC assay is based on structural 
complementation of an intact fluorescent protein when two complementary non-
fluorescent fragments are brought together by a pair of interacting proteins [123]. 
(Fig.:1.7) When the proteins interact in a suitable orientation and conformation, the 
fluorescent protein is non-covalently reconstituted and fluorescence is generated. If the 
proteins do not interact, or do not do so in the appropriate orientation, no fluorescence 
is emitted [124]. BiFC was introduced in 2002 to study interactions between basic 
leucine zipper (Bzip) and Rel family transcription factors in cellular environment using 
the COS-1 cell line [125]. Since then, BiFC has been used successfully in different 
model organisms, such as mammalian cell lines, plants, nematodes, yeast, bacteria 
and even rodents [122, 126, 127]. One of the limitations of BiFC is its inability for 
visualizing dynamic interaction changes [128-130]. However, the fact that reconstitution 
of the fluorophore lead to stabilization of the protein complex turns out to be useful 
because it allows the selective enrichment of dimeric/oligomeric species. More 
precisely, for the study of neurodegenerative diseases, the stabilization of certain 
proteins could be useful because it enables the study of species that might be 
transient, such as those generated in the protein aggregation process. In the field of 
Fig.: 1.7 - Schematic representation of the BiFC assay. A part of Venus  protein is  fused with N-terminal  of α-Syn and 
the other part is  fused with C-terminal of α-syn. When two complementary non-fluorescent fragments  are brought 
together due to α-Syn dimerization, the fluorophore is reconsti tuted. 
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PD, BiFC has been used to visualize α-Syn oligomers and to observe their modulation 
by HSP70 [128], to investigate the effect of CHIP on α-Syn oligomerization [128, 130]. 
Multicolor BiFC has been used to investigate dopamine D2 and adenosine A2A receptor 
oligomerization [131]. Very recently a new animal AAV-based model using the BiFC 
assay allowing the direct detection of α-Syn oligomers in vivo was developed [122]. 
In this project, taking into account the potential of this technique we used the 
BiFC assay in order to study α-Syn oligomers long-distance transport in neurons in 
vivo.  
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Objective 
As outlined in the Introduction chapter, development and characterization of α-
Syn-based animal models are crucial steps to understand pathogenesis of the 
Parkinson’s disease. In recent years, studies have pointed to α-Syn oligomers as the 
toxic species of α-Syn [94, 132], playing a key role in PD pathogenesis. Previous 
studies have also shown the applicability of protein complementation assay to detect α-
Syn oligomers in vitro [128-130, 133] and in vivo [122], providing a tool to dissect the 
role of α-Syn oligomers in PD. Thus, the major goal of this study was to develop and 
characterise a new animal model for detection of α-Syn oligomers in vivo as well as 
investigate the Parkinson pathology propagation. More specifically our aim was to 
study whether and how different forms of a-syn (especially oligomeric and fibril) are 
transported in neurons, whether transporting a-syn oligomers and fibrils can contribute 
to aggregation. To pursue this goal we overexpressed the human α-Syn in different 
brain regions affected in the PD, such as substantia nigra, striatum or motor cortex, 
using an AAV-mediated gene delivery of two constructs containing complementary 
halves of a fluorescent protein linked to human α-Syn. This approach enables the study 
of α-Syn oligomers formation and transport in neurons and neuronal pathways.  
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Chapter 2. METHODS 
Virus preparation 
The viral vectors pAAV2-Venus1NPart-linker-hSyn-WPRE (V1S) and pAAV2-
hSyn-Venus2CPart-WPRE (SV2) were constructed by inserting the 
human SNCA gene, fused to either the N-terminus half of venusYFP (V1S) or the C-
terminus half of venusYFP (SV2) (Fig.:2.1) into the EcoRV and NheI sites of the 
pAAV2-WPRE vector [122]. pAAV2-Venus-W PRE was constructed by inserting the 
venusYFP gene into the XhoI and NheI sites of pAA  V2-WPRE vector. The expression 
of the transgene is driven by the synapsin-1 promoter and enhanced using a 
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). Briefly, 
transfer plasmids carrying AAV2 ITRs coding for a human wt α-Syn, downstream to a 
synapsin-1 promoter, were generated as described in [134]. The transfection into HEK 
293 cells was carried out using the calcium-phosphate method, and included the 
packaging plasmids encoding AAV6 capsid proteins. 
 
 
 Fig.: 2.1 -  Schematic representation of the BiFC constructs  
  
Animals 
Adult female Sprague Dawley rats, weighing 225-250 g at the time of surgery, 
were housed two to three per cage with ad libitum access to food and water through a 
12h light/dark cycle. All procedures were approved and conducted in accordance with 
guidelines set by the Ethical Committee for the use of laboratory animals in the Lund-
Malmö region and the European Ethical Committee (EEC). In order to assess whether 
and how oligomerized α-Syn transports throughout the CNS in vivo we set 3 
experimental groups of animals: 
 CX Group: AAV V1S+SV2 or Venus injection into the motor cortex  
 SN Group: AAV V1S+SV2 or Venus injection into the substantia nigra  
 ST Group: AAV V1S+SV2 or Venus injections into the striatum 
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Surgical Procedure 
All surgical procedures were performed under general anaesthesia using a 20:1  
mixture of fentanylcitrate (Fentanyl) and medetomidin hypochloride (Dormitor) 
(Apoteksbolaget, Sweden) injected intra peritoneal (IP). Rats were placed in a 
stereotaxic frame (Stoelting), the surgical site was shaved and sterilized with ethanol 
and a 2 cm incision was made along the midline.  Solution containing the AAV was 
injected using a 5 µl Hamilton syringe fitted with a glass capillary (outer diameter of 250 
µm). The groups of animals injected in motor cortex, substantia nigra or striatum 
comprised 8, 17 and 23 rats, respectively.  
AAV injection: 2µl of the pAAV2-Venus1NPart-linker-hSyn-WPRE (V1S) plus pAAV2-
hSyn-Venus2CPart-WPRE (SV2)  (mixture 1:1), or pAAV2-Venus-WPRE  solution 
were infused at a rate of 0.2 µl/min and the needle was left in place for an additional 3 
minute period before it was slowly retracted at a rate of 1mm per minute. Injection was 
carried out unilaterally on the right side, targeting the substantia nigra at coordinates: 
antero-posterior: - 5.3 mm, medio-lateral: -1.7 mm , dorso-ventral: -7.2 mm, the 
striatum: antero-posterior: +0.5 mm, medio-lateral: -3.5 mm , dorso-ventral: -4.8 mm, 
(Fig.:2.2) or the motor cortex: antero-posterior: +2.0 mm, medio-lateral: -1.8 mm , 
dorso-ventral: -1.5 mm below dural surface, with bregma as a point of reference. The 
viral concentration used was of 1,25*1013 gc/ml. The total viral load per injection 
(2µl)/animal was 2,5*1010 gc. Equal number of gc/ml were used for α-Syn (SV1+SV2) 
and control (Venus) AAV injection.  
 
Fig.: 2.2- Schematic representation of the AAV stereotaxic injection. Stereotaxic injection of the AAV was 
performed targeting the s triatum. (Courtesy of Itzia Ferrer)  
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Sciatic Nerve crush was performed bilaterally in the group of animals injected in the 
motor Cortex as described previously [135]. Briefly, animals were placed in prone 
position. After asepsis a 2 cm incision was made over the lateral aspect of the hind 
limb, muscles were separated in order to expose the sciatic nerve and then, the crush 
was done with a glass rod and silk suture (10 seconds each). The crush procedure 
included double crushes, with a distance of 1-2 mm between them. (Fig.: 2.3)  Lastly 
the skin was sutured with (4-0) stitches. 
 
 
 
 
 
 
 
 
 
 
 
Behavioural Testing 
Assessment of behavioural function was performed in the groups of animals 
that were injected in substantia nigra and striatum 4, 8 and 12 weeks after injection of  
the viral vector using three different tests. Rats were food restricted and maintained at 
85% free-feeding bodyweight throughout habituation and testing. 
Corridor Task: Lateralised sensorimotor integration was measured using a task that 
was first established in 2005 [136]. At the first time point, rats were habituated to the 
corridor by scattering sugar pellets (40 mg; TestDiet) along the floor and allowing them 
to freely explore for 10 min on 5 consecutive days prior to testing. When testing began, 
fasted rats were first placed in an identical, but empty, corridor for habituation for 5 min, 
Spinal cord 
Sciatic  nerve 
Muscle 
1-2 
 mm 
Surgical 
Injury site 
Fig.: 2.3 - Shematic representation of the Sciatic nerve crush.  
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before being transferred to one end of the testing corridor (Fig.: 2.4). The number of 
ipsilateral and contralateral retrievals made by each rat was counted and trials were 
terminated when the rat made a total of 20 retrievals or a maximum time of 5 min had 
elapsed. A ‘retrieval’ is defined as the animal poking its nose a pot, whether or not a 
pellet is eaten, and a new retrieval can only be made by investigating a new pot. Data 
are expressed as percentage of contralateral retrievals of the total retrievals made from 
both sides of the body axis. 
 
Cylinder Task: Forelimb use asymmetry during exploratory activity was analysed by 
videotaping rats. They were put in a transparent glass cylinder, a mirror was placed to 
the side of the cylinder at an angle to enable the recording of forelimb movements even 
when the animal was turned away from the camera (Fig.: 2.5A). Trials were terminated 
when the rat made a total of 20 forepaw touches or a maximum time of 5 min had 
elapsed. The number of ipsilateral and contralateral touches made by each rat was 
counted. Data are presented as a percentage of contralateral paw touches. 
Fig.:2.4 - Corridor Task.  A mouse is  fi rst placed into an identical  but empty habituation corridor for 5 min prior to 
being placed at the s tart of the testing corridor. The testing corridor has  adjacent pairs  of pots  that contain sugar. 
(Adapted from Grealish, S., et al ., 2010) [1] 
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Stepping Task: Forelimb akinesia was analysed videotaping rats performing the 
stepping task. On 3 days preceding the test, animals were handled by the experimenter 
to familiarise them with the test procedure. The test was performed on three 
consecutive days. Briefly, the rat was held by the experimenter fixing both hind limbs 
with one hand and the forelimb not to be monitored with the other [137], while the 
unrestrained forepaw was touching the table (Fig.: 2.5B). The rat was moved sideways 
along the table surface (90 cm in 5 s). This procedure was repeated three times for 
each forelimb. The number of adjusting steps in the forehand direction was counted. 
The mean of data obtained on three testing days constituted the final dependent 
variable.  
 
Tissue processing and immunohistochemistry 
All animals from the groups injected in the substantia nigra and striatum were 
sacrificed 5 days after the last behavioural test, and the ones from the group injected in 
the motor cortex were sacrificed 7 hours after the sciatic nerve crush. The rats were 
deeply anaesthetised with 0.6 ml sodium pentobarbital IP. (Apoteksbolaget, Sweden) 
and then perfused through the ascending aorta with 50 ml saline (0.9% w/v), followed 
by 250 ml ice-cold paraformaldehyde (4% w/v in 0.1 M phosphate buffered saline). The 
brains of the SN, ST and CX group and, spinal cord and sciatic nerve from the CX 
group were removed, post-fixed for 12 h in 4% paraformaldehyde and cryoprotected in 
sucrose (25% w/v in 1% phosphate buffered saline) before being sectioned on a 
Fig.:2.5 – A) Cylinder Task; B) Stepping Task. A) A rat’s  forelimb use during exploratory activi ty. B) A rat being held 
by the experimenter fixing both hind limbs  with one hand and the forelimb not to be monitored with the other 
hand. 
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microtome (Microtome Leica SM 2010R) in the case of brain and spinal cord, or in a 
cryostat (Cryostat Leica CM 3050 S) in the case of the sciatic nerve. Regarding the 
brain, coronal sections were collected in 8 series at a thickness of 40 µm. In the case of 
the spinal cord coronal and sagittal sections were collected from the cervical, thoracic 
and lumbar regions at a thickness of 40 µm. The sciatic nerve samples were sectioned 
at 16 µm in the cryostat and collected to the glass slide. All the collected samples were 
kept at 4°C. 
Immunohistochemical staining was performed on free floating sections (brain 
and spinal cord) or on mounted slides (sciatic nerve) using antibodies raised against 
tyrosine hydroxilase (TH) (mouse, 1:10000; Immunostar), tyrosine hydroxilase (TH) 
(rabbit, 1:500; Pelfreeze), Green Fluorescent Protein (GFP) (Chicken, 1:20000; 
Abcam), ionized calcium-binding adapter (IBA1) (rabbit, 1:500; Wako Chemicals), glial 
fibrillary acidic protein (GFAP) (rabbit, 1:500 ; Dako) for brain staining  , Synuclein-
1(mouse, 1:400; BD Biosciences), for sciatic nerve staining, α-synuclein (211) (mouse, 
1:1000; Santa Cruz Biotechnology), Phospo-Ser129 α-synuclein (rabbit, 1:1000; 
Abcam) for brain, sciatic nerve and spinal cord staining, and Synaptophysin (G96) 
(rabbit, 1:2000; R.Jahn), Rabphilin-3A antisera full length (rabbit, 1:5000; Jia-Yi Li) , 
Rab-3A (mouse, 1:2000; Synaptic Systems) for sciatic nerve staining. Sections were 
rinsed three times in PBS between each incubation period and all steps, except the 
incubation with the primary antibody, were performed at room temperature with three 
10 min washes in PBS-TX (0,1 – 0,5% triton X-100) between each step. Primary 
antibody was incubated at 4⁰C overnight. Sections were mounted and coverslipped 
using 50% glycerol (PBS) and kept at 4°C. 
For diaminobenzidine (DAB) staining sections were treated with 100% methanol 
and 3%H2O2 for 30 min to inhibit endogenous peroxidases, permeabilized in PBS-TX 
for 30 min and blocked in 5% BSA in PBS-TX for 1 h. Sections were incubated with 
primary antibody in 2% BSA over night at 4°C followed by incubation with biotinilated 
secondary antibody for 2 h at room temperature and avidin-biotin (Vectastain kit; 
Vector) for 1 h at room temperature. Sections were incubated with 3,3-
diaminobenzidine (DAB; Vector), rinsed in PBS, mounted, dehydrated and 
coverslipped using DPX mounting medium.  
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Microscopy and stereology 
Fluorescence images were obtained using a confocal laser-scanning microscope 
(Zeiss LSM 510, Jena, Germany) using ZEN software or a fluorescence microscope 
(Olympus BX53) using Cell Sens Dimension software. All images were analysed using 
ImageJ. For an overview of the distribution of total α-Syn and pSer129 α-Syn in the 
brain of AAV-injected animals, sections from different brain regions were scanned 
using EPSON perfection V750 PRO with Silver Fast software. 
Assessment of the total number of TH+ neurons in the substantia nigra was 
made according to the optical fractionator principle, using a Leica Leitz DM RBE and 
the Stereo Investigator software. All the sections covering the substantia nigra from two 
series were included in the counting procedure. A coefficient of error <0.10 was 
accepted. Striatal TH+ fibre density was measured by densitometry using the ImageJ 
software (Version 1.47v, National Institute of Health, USA). The striatum, ipsilateral and 
contralateral, was outlined and the mean intensity in the region of interest was 
determined. The measured values were corrected for non-specific background staining 
by subtracting values obtained from the corpus calosum. The data are expressed as a 
percentage of the corresponding area from the contralateral side.  
 
Statistical Analysis 
Data is expressed as a group mean ± SD (standard deviation) unless stated 
otherwise.  Statistical analysis was performed using GraphPad Prism software, except 
for the behaviour assessment where statistical analysis was performed using SPSS 21 
software. Datasets from Behaviour assessment were tested for statistical significance 
using t-test to compare between timepoints, Friedman test to compare the differences 
between the timepoints within one group of animals, and Man-Whitney test as non-
parametric test. A paired Student’s t-test was used to compare the number of midbrain 
TH+ neurons on the contra- and ipsilateral-side of the injection. Linear regression was 
performed on the densitometric values.   
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Chapter 3. RESULTS 
In this study we developed and characterized a novel animal model of PD that 
enables us to monitor α-Syn oligomers in vivo. We used a mix of two AAV constructs 
expressing human wt α-Syn fused with either the N- or C-terminus half of Venus 
protein (AAV V1S+SV2). An AAV construct expressing Venus alone was used as a 
control. In order to assess whether and how oligomerized α-Syn transports throughout 
the CNS in vivo we set 3 experimental groups of animals: 
 CX Group: AAV V1S+SV2 or Venus injection into the motor cortex  
 SN Group: AAV V1S+SV2 or Venus injection into the substantia nigra  
 ST Group: AAV V1S+SV2 or Venus injections into the striatum  
AAVs were stereotactically injected into the respective brain target area of Sprague 
Dawley rats.  
 
CX Group (motor cortex-injected)  
Transport of oligomerized α-synuclein via the corticospinal tract 
The CX group constituted of 8 animals (4 V1S+SV2 + 4 Venus). All animals 
were subjected to stereotactic AAV injection weighting 225-250 g targeting the motor 
cortex. Sciatic nerve crush was performed 9 weeks after the AAV injection with the 
objective of investigating the accumulation of the human α-Syn near the site of the 
crush. Animals were sacrificed 9 weeks post AAV injection and brain, spinal cord and 
sciatic nerve samples were prepared for analysis. 
 
 
 
 
 
 
 
 
 
 
AAV 
injection 
Sciatic Nerve 
Crush 
9 weeks 
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9 weeks post viral injection we were able to observe the BiFC signal at the 
place of injection (motor cortex) (Fig.:3.1 A). Moreover, we have detected the BiFC 
signal in the entire cortico-spinal tract, (Fig.:3.1) being evident in brain regions including 
the striatum (Fig.:3.1 B), thalamus (Fig.:3.1 C), midbrain (Fig.:3.1 D), pons  (Fig.:3.1 E) 
and even in the spinal cord(Fig.:3.1 H).  
 
 
 
 
 
 
 
 
 
 
 
Fig.:3.1 - Detection of α-Syn oligomerization in the Corticospinal tract using protein complementation assay . 
Schematic representation of the brain areas  where the BiFC signal was detected (top). Coronal  sections  from rats 
injected with AAV V1S+SV2 were mounted onto glass slides  and directly imaged under a  fluorescence 
microscope.(Bottom) Reconsti tuted Venus fluorescence is  visible in the ipsilateral side of the brain in the injection 
site (A), Striatum (B), Thalamus  (C), Midbrain (D), Pons  (E), Medulla oblongata  (F, G) and in the contralateral  side in 
the spinal cord (H). Scale bar: 500 µm in the images A-E and 250µm in the images  F-H. 
A)                              B)                                       C)                                        D)          
   E)                                       F)                                               
   G)                                       H)                                               
A                                    B                                     C                                    D        
E                                    F                                     G                                    H        
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More specifically, we were able to detect oligomerized α-Syn in the cell bodies and 
dendrites at the site of injection and (Fig.:3.2 A) in the neuronal projections in the 
subsequent brain regions (Fig.:3.2 B and C). Interestingly, we have observed axonal 
accumulation of α-Syn oligomers in the midbrain (Fig.:3.2 D), pons (Fig.:3.2 E) and 
spinal Cord (Fig.:3.2 F). 
 
 
 
 
Microscopic analysis of the brain samples enabled us to conclude that the AAV 
injection was well targeted and that there was formation of α-Syn oligomers readily 
observed by reconstitution of Venus fluorescence (BiFC signal). Moreover, oligomeric 
a-Syn forms were transported from the motor cortex via the corticospinal tract into the 
spinal cord.  
 
 
 
 
Fig.: 3.2 – Detection of α-Syn oligomerization in different brain areas using protein complementation assay. 
Coronal sections  from rats  injected with AAV V1S+SV2 were mounted onto slides and directly imaged under a 
fluorescence microscope. Reconsti tuted Venus is  visible in cell bodies  at the injection si te as  well  as in the neuronal 
projections  through the corticospinal  tract. Axonal accumulation of α-Syn oligomers  is  seen in regions  such as 
midbrain (D), pons (E) and spinal  cord (F). Scale bar: 25µm 
Motor Cortex                                Striatum                                          Thalamus 
Midbrain                                         Pons                                                 Spinal cord 
A                                                      B                                                       C 
D                                                      E                                                       F  
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Through the BiFC signal we were able to detect the fraction of human α-Syn 
that was dimerized or oligomerized. In order to detect the total human α-Syn protein 
load in the brain, we performed immunohistochemistry (IHC) analysis using an 
antibody against human α-Syn (Fig.:3.3). Human α-Syn was found throughout the 
corticospinal tract. As expected, we found more α-Syn positive neurons/neuronal 
projections in the specific brain areas when compared to BiFC, however, the overall  
pattern of distribution in the corticospinal tract was similar to BiFC (Fig.:3.3). No α-Syn-
positive structures were observed in the Venus-injected animals, showing the 
specificity of the α-Syn antibody to human α-Syn. Additionally, we performed an IHC 
analysis using an anti-GFP antibody to visualize the distribution of the Venus protein in 
the control group (Venus-injected animals).  The overall distribution profile of the Venus 
was similar to the human α-Syn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GFP             211 
Negative control           GFP                           α-Syn 
CX group 
Fig.: 3.3 – Histological overview of transduced brain regions. Coronal  brain sections  were stained with antibodies 
recognizing the syn211 against human α-Syn and an antibody against GFP. Negative control  animals were s tained 
with human α-Syn (211) antibody to confi rm specifici ty. Transduction patter was  very similar in the AAV V1S+SV2 
(s tained for human α-Syn) and the AAV Venus  group (s tained for GFP) with a  very intense immunoreactivi ty in the 
cortex. No s taining was  observed in the Negative control  animals  (AAV Venus  stained for human α -Syn), 
confi rming the speci ficity of this antibody towards human α-Syn.  
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Several studies suggest that phosphorylation at serine 129 (pS129) may play 
an important role in regulating α-Syn fibrillization, aggregation, LB formation and 
toxicity in different model systems [54, 72, 73, 138, 139]. In order to evaluate the 
presence of phosphorylated α-Syn in our model, we performed an IHC assay using an 
antibody against human α-Syn pSer129. As shown in the (Fig.:3.4),  we were able to 
detect pSer129 α-Syn in the cell bodies and neurites in the cortex (Fig.:3.4 A), as well 
as in the neuronal projections of other zones of the corticospinal tract. We were also 
able observe accumulated α-Syn pSer129 in some of the axons as well (Fig.:3.4 B, E 
and F) 
 
 
 
 
 
 
Because we have seen presence of total human α-Syn and even pSer129 α-
Syn in the thoracic part of the spinal cord, reflecting its transport/spreading from the 
cortex, it prompted us to check for the accumulation of proteins near the sciatic nerve 
crush site. In case we would be able to see accumulation of human α-Syn, it will 
suggest that there had been trans-synaptic transfer of these oligomeric species from 
the upper motor neuron to the lower motor neuron.  Initially, and to define the proximal 
and distal side of the crushes we stained for Rabphilin and Rabphilin-3A antibodies, the 
proteins involved in the regulation of synaptic vesicle fusion and that are known to be 
Cortex Striatum Striossomes 
Thalamus Midbrain Pons 
Fig.: 3.4 –Histological analysis of phosphor Serine 129 α-Syn expression. Histological analysis of the brain 
sections  revealed high expression of phosphor Serine 129 α-Syn (pS129 α-Syn) in di fferent regions  of the 
corticospinal  tract. Neurons  of the site of injection (A) displayed a  high incidence of pSer129 within the cell  body 
and axons  while the other regions  presented high incidence of pS129 within the axonal  projections . Large pS129 
positive s tructures, believed to be axonal swellings , were present throughout the striatum (B and C), thalamus (D), 
midbrain (E) and pons (F). Scale bar: 50µm 
A                                                       B                                                       C  
D                                                       E                                                       F 
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primarily transported in an anterograde manner, which means that we can use them as 
markers of the proximal site. Than we tried to stain by immunofluorescence the human 
α-Syn, but the result was not conclusive. (Data not shown) 
In conclusion, we were able to observe transport of oligomerized α-Syn via the 
corticospinal tract after the AAV injection into the motor cortex. Additionally, the 
phosphorylated form of α-Syn on serine 129 was detected in the axonal profiles where 
the oligomerized α-Syn was transported as well as axonal accumulation, reflecting 
phenomena of neurodegeneration. 
 
SN and ST Groups (substantia nigra-  and striatum- injected) 
Transport of oligomerized α-Synuclein via the nigrostriatal pathway with 
signs of axonal degeneration 
The nigrastriatal dopaminergic system is mainly affected in PD. The nigrostriatal 
pathway projects from the substantia nigra pars compacta to the striatum. Taking this 
into consideration, in the next step we performed AAV injection targeting the 
nigrostriatal pathway, more precisely substantia nigra and striatum. We had 2 groups of 
animals according to the area targeted with the AAV injection. The SN group was 
constituted of 23 animals (12 V1S+SV2 and 11 Venus) and the ST group was 
constituted of 17 animals (9 V1S+SV2 and 8 Venus). According to the following 
schematic representation, all animals were subjected to AAV injection weighting 225-
250 g targeting the substantia nigra or striatum, respectively. Motor function was 
assessed in both groups 4, 8 and 12 weeks after viral injection using three different 
tests, the Cylinder, Corridor and Stepping test (for detailed description see Chapter2. 
Methods, section Behavioural Testing). Animals were sacrificed 12 weeks post-AAV 
injection and brain samples were collected for analysis. 
 
 
 
 
 
AAV 
injection 
Motor Behaviour  Assesment: 
 Corridor Task 
 Cylinder Task 
 Stepping Task 
Behaviour  
Assesment 
Behaviour  
Assesment 
4 weeks 8 weeks 12 weeks 
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SN group presented strong BiFC signal in cell bodies and dendrites of the SNpc 
(injection site) (Fig.:3.5 A) and also in the axonal projections in the striatum, (Fig.:3.5 B) 
which strongly suggests the spreading of the α-Syn oligomeric forms through the 
nigrostriatal pathway, the main dopaminergic pathway. We also observed BiFC signal 
in other brain regions such as thalamus and midbrain, showing that apart from our 
main target – the nigrostriatal dopaminergic pathway, we targeted other systems to a 
certain extent.  
 
 
 
 
 
Fig.: 3.5 – Detection of α-Syn oligomerization in the nigrostriatal pathway using protein complementation 
assay. Coronal sections from rats injected in substantia nigra with AAV V1S+SV2 were mounted onto slides and 
directly imaged under a  fluorescence microscope. Reconstituted Venus  is visible in cell bodies  in substantia nigra 
pars compacta (injection site) (A) and in the neuronal projections  in Striatum (B). Scale bar: 500µm (A), 250µm (B), 
25µm (A’ and B’) 
A                                                                                               A’  
B                                                                                               B’ 
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The ST group showed strong BiFC signal in the cell bodies of the striatum 
(injection site) (Fig.:3.6 B) and in the SNpr (Fig.:3.6 A). This group also showed some 
BiFC signal in the thalamus too, but not as wide spread in the midbrain as the SN 
group. 
 
 
 
 
As in the case of the CX group, through the BiFC signal we were only able to 
detect the fraction of human α-Syn that was dimerized or oligomerized. In order to 
detect the total load of human α-Syn protein, brain sections were subjected to IHC 
using an antibody against human α-Syn. Control animals were additionally subjected to 
IHC using an antibody against GFP (recognizes Venus protein). In the ST group, 
Fig.: 3.6 – Detection of α-Syn oligomerization in the nigrostriatal pathway using protein complementation 
assay. Coronal  sections  from rats  injected in s triatum with AAV V1S+SV2 were mounted onto slides  and directly 
imaged under a  fluorescence microscope. Reconstituted Venus  is  visible in cell bodies of s triatum (injection site) 
(B) and in substantia nigra pars reticulata (B). Scale bar: 500µm (A), 250µm (B), 25µm (A’), 50µm (B’) 
A                                                                                            A’  
B                                                                         B’ 
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human α-Syn was found in the striatum (cell bodies and neuronal projections) and in 
SNpr. 
 As expected, the extent of total α-Syn expression was higher than what was observed 
through the BiFC, however the overall distribution was similar to the BiFC. Regarding 
the SN group, the spread of the α-Syn protein is much wider than in the ST group. 
(Fig.:3.7) Human α-Syn was found throughout the nigrostriatal pathway, but moreover 
was found in other brain regions such as thalamus and midbrain, being detected as 
caudal as the cervical part of the spinal cord. This confirms once again that apart from 
our main target – the nigrostriatal dopaminergic pathway, we targeted other systems to 
a certain extent as well. For both groups and as expected the overall distribution profile 
of the Venus was similar to the human α-Syn. 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
ST group  
 
SN group  
GFP             α-Syn GFP               α-Syn 
Fig.: 3.7 – Histological overview of transduced brain regions. For both ST and SN goups coronal  brain sections 
were s tained with antibodies  recognizing the syn211 against human α-Syn and an antibody against GFP. Negative 
control  animals were s tained with syn211 antibody to confi rm speci fici ty. (not shown) Transduction pattern was 
very similar in the AAV V1S+SV2 (s tained for human α-Syn) and the AAV Venus group (s tained for GFP) with a  very 
intense immunoreactivi ty in the cortex. No s taining was  observed in the Negative control  animals (AAV Venus 
stained for human α-Syn), confi rming the specifici ty of this antibody towards  human α-Syn.  
Parkinson pathology propagation and long-distance transport in neurons 
 
 
54 
 
In SN injected animals, closer examination revealed the presence of human α-
Syn in cell bodies and neuronal fibers in the ipsilateral SNpc (Fig.:3.8 A) contrasting 
with the lack of α-Syn in the contralateral substantia nigra (Fig.:3.8 C) . Similarly to 
what we observed in the CX group we were also able to detect pSer129 α-Syn, the 
pathology-linked form of α-Syn, in the ipsilateral substantia nigra cell bodies and 
neurites (Fig.:3.8 B).  
 
 
 
Human α-Syn pS129 α-Syn 
Fig.: 3.8 - Histological analysis of α-Syn expression in substantia nigra. Histological analysis  of the brain sections 
of AAV injected animals of SN group revealed high expression of human α-Syn (211)(left) and phosphor Serine 129 
α-Syn (pS129 α-Syn)(right) in the cell  bodies and fibers  of the ipsilateral  substantia nigra. (A, B, A’ and B’) The 
contralateral  side presented no expression of α-Syn. (C and D) Scale bar: 200µm (A ,B, C and D), 50µm (A’ and B’) 
A                                                                                    B 
A’                                                                                  B’  
C                                                                                    D 
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Furthermore, total human α-Syn (Fig.:3.9 A) as well as pSer129 α-Syn (Fig.:3.9 
B) was detected in axonal projections in the striatum fibers. And accumulation of the 
phosphorylated form of α-Syn in the cell bodies and axons in striatum was detected 
(Fig.:3.9 B, arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human α-Syn pS129 α-Syn 
Fig.: 3.9 - Histological analysis of  α-synuclein expression in the  striatum. Histological  analysis of the brain 
sections  of rats  AAV injected in substantia nigra revealed high expression of human α-Syn (211)(A) and phosphor 
Serine 129 α-Syn (pS129 α-Syn)(B) in s triatum fibers  with some visible signs of axonal  accumulation. (arrow) Scale 
bar: 50µm  
A                                                                            B 
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In sections from animals of ST group, closer examination revealed the presence of 
human α-Syn in the striatum (injection site) (Fig.:3.10 B) and SNpr (Fig.:3.10 A). 
Similarly to what we observed in the CX and SN group we were also able to detect 
pSer129 α-Syn, the pathology-linked form of α-Syn, in the ipsilateral substantia nigra 
(Fig.:3.11 A) and striatum (Fig.:3.11 B), contrasting with the lack of pSer129 α-Syn in 
the contralateral side (Fig.:3.11 C and D). 
 
 
 
 
Substantia nigra                                                  Striatum  
Fig.: 3.10 - Histological analysis of α-Synuclein expression in substantia nigra and striatum. Histological  analysis 
of the brain sections of AAV injected animals of ST group revealed high expression of human α-Syn (211) in the 
s triatum (injection si te) (B) and in substantia nigra pars reticulata (A)  Scale bar: 200µm (A and B), 50µm (A’ and 
B’) 
A                                                                               B 
A’                                                                               B’  
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Interestingly, we have observed altered axonal morphology – axonal swellings- in the 
striatum of the animals injected with AAV V1S+SV2 (Fig.:3.12 A) when compared to 
the control Venus group (Fig.:3.12 B). The axonal swellings present in the animals 
injected with AAV V1S+SV2 might be due to block of axonal transport and axonal 
Substantia nigra                                                         Striatum  
Fig.: 3.11 - Histological analysis of pathology-linked form of α-Synuclein expression in substantia nigra and 
striatum. Histological  analysis of the brain sections  revealed high expression of phosphor Serine 129 α-Syn (pS129 
α-Syn) in the cell  bodies of s triatum (injection site) (B) and fibers  of the ipsilateral  substantia nigra pars reticulate 
(A). The contralateral side presented no expression of pS129 α-Syn. (C and D) Scale bar: 200µm (A, B, C and D), 
50µm (A’ and B’) 
A                                                                                      B 
A’                                                                                     B’  
C                                                                                       D 
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degeneration. Altogether these results show that α-Syn oligomers were formed and 
transported antero-gradely through the nigrostriatal pathway. 
 
 
 
 
 
The nigrostriatal pathway is the main dopaminergic pathway in the brain and is 
the one mainly affected in PD giving rise to the motor symptoms [39]. To investigate 
whether there were any deﬁcits in motor function in our model, we performed three 
distinct tests of spontaneous motor performance at 4, 8 and 12 weeks post AAV 
injection. (for detailed description see Chapter2.Methods, section Behavioural Testing) 
There was no significant difference between the Venus and α-Syn groups in any of the 
timepoints in corridor and cylinder task. However, in the stepping task at 4 weeks the α-
Syn group showed a significantly reduced number of adjusting steps by the left paw 
(Fig.:3.13), suggesting impairment in the motor function of the limb controlled by the 
side of the brain where the injection was made. However, this impairment was not 
observed at later time-points, suggesting a compensatory mechanism. 
Dopamine has been described as an important neurotransmitter involved in 
movement control due to the association between the depletion of striatal DA and 
motor deficits observed in PD.  Synthesis of DA is limited by the activity of enzyme 
tyrosine hydroxylase. 
 
V1S+SV2 Venus 
Fig.: 3.12 – Detection of α-Synuclein oligomers in the  striatum.  Coronal  sections  from the s triatum of rats 
injected with AAV V1S+SV2  and AAV Venus in the substantia nigra were imaged for the presence of Venus 
fluorescence. Venus  fluorescence is  detected in both AAV V1S+SV2 (A) and AAV Venus  (B) injected animals. 
However, only the animals injected with the AAV V1S+VS2 presented punctuate pattern resembling axonal 
accumulation (A) (arrow). Scale bar: 50µm 
A                                                                                 B 
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SN group 
 
ST group 
 
 
 
 
 
 
 
Fig.: 3.13 – Behavioural assessment of motor functions. At 4, 8 and 12 weeks  post vi ral injection, animals were 
subjected to 3 tests of motor performance.   Error bars  +/- 1 SE  
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 Overexpression of α-Syn in cells has been showen to lead to a significantly 
reduced TH activity and DA synthesis [140, 141]. To determine if the presence of α-Syn 
oligomers in the substantia nigra resulted in dopaminergic cell death we examined 
neuronal cell death 12 weeks after viral injection. Stereological analyses revealed no 
significant death of the TH+ cells in the animals injected with α-Syn when compared to 
the control (Fig.:3.14). Furthermore, we analysed the TH levels in the dorsolateral 
striatum to examine if there was a degeneration of the axons of the dopaminergic cells 
from SNpc projecting to striatum. Although there was a trend of decrease in the TH-
positive fibers of the dorsolateral striatum of the ipsilateral side in the α-Syn injected 
animals, it did not reach statistical significancy (Fig.:3.14). 
 
 
 
 
 
 
 
 
 
 
Fig.: 3.14 – Assessment of midbrain dopaminergic TH+ cells and  TH+ innervation in striatum. Unbiased 
s tereological analysis of TH immunopositive cells in coronal  sections across the s ubstantia nigra of SN group 
animals  was  performed using DAB. TH+ innervation in s triatum of SN and ST groups  animals  was measured using 
semiquantitative densi tometry. Regarding SN group analyses  revealed no signi ficant death of the TH + cells in the 
AAV V1S+SV2 injected animals when compared to AAV Venus  injected ones ; s triatum densitometry revealed no 
signi ficant di fferences  but a  slight tendency of decrease in the AAV V1S+VS2 injected animals compared with the 
AAV Venus ones .  ST group revealed no significant di fferences in the TH+ fibers of s triatum, showing an interesting 
decrease in the AAV venus injected animals. ns : non signi ficant 
 
* 
SN group 
 
ST group 
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There is evidence suggesting that inflammation contributes to the 
pathophysiology and aetiology of neurodegenerative disorders [142-144]. Moreover, 
inflammatory reactions involving microglia, astrocytes, and lymphocytes have been 
described in several animal models of PD [145-147] and in PD patients [148, 149]. 
Several studies link striatal neuroinflammation to neurotoxicity and disease progression 
as a result of α-Syn aggregation [147, 150]. To assess striatal inflammation and/or 
gliosis in our model striatal sections were subjected to IHC analysis for GFAP, an 
astrocytic marker and Iba1, a microglial marker, to determine whether the presence of 
α-Syn oligomers in our model resulted in an inflammatory response and gliosis.  
 
 
 
 
 
 
Fig.: 3.15 – Absence of neuroinflammation in the striatum of SN group. Striatal  coronal sections were 
immunostained for Iba1 (C and D) or GFAP (A and B) expression. Comparing Ipsi - (B and D) and contralateral- 
side (A and C) of AAV V1S+SV2 injected animals there is no di fference in the Iba1 or GFAP expression. Scale bar: 
500µm 
 
A                                                               B 
C                                                                     D 
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Immunofluorescence analysis revealed no significant difference in the 
expression of GFAP (Fig.:3.15/16 A and B) or Iba1 (Fig.:3.15/16 C and D) in AAV 
V1S+SV2 injected animals of SN (Fig.:3.15) and ST (Fig.:3.16) groups comparing 
ipsilateral to the contralateral side. Therefore, we did not observed any signs of gliosis 
or microglia-driven inflammation in our model 12-weeks post injection. 
 
 
 
 
 
  
 
 
Fig.: 3.16 – Absence of neuroinflammation in the striatum of ST group. Striatal  coronal sections were 
immunostained for Iba1 (C and D) or GFAP (A and B) expression. Comparing Ipsi - (B and D) and contralatera-l  side 
(A and C) of AAV V1S+SV2 injected animals there is no di fferen ce in the Iba1 or GFAP expression. Scale bar: 500µm 
 
A                                                                          B 
C                                                                        D 
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Chapter 4. DISCUSSION 
In recent years, studies have pointed to α-Syn oligomers as the toxic species of 
α-Syn [94, 132], playing a key role in PD pathogenesis. Previous studies have shown 
the applicability of protein complementation assay to detect α-Syn oligomers in vitro 
[128-130, 133] and in vivo [122], providing a tool to dissect the role of α-Syn oligomers 
in PD. Several animal models of synucleinopathies have been valuable for studying the 
etiopathology, including models overexpressing α-Syn [113, 117, 118, 121]. However, 
all the available models so far only allowed the detection of α-Syn oligomers based on 
indirect biochemical approaches. In this study we developed and characterised a new 
animal model for detection of α-Syn oligomers in vivo. We overexpressed the human α-
Syn in different brain regions affected in the PD, such as substantia nigra, striatum or 
motor cortex, using an AAV-mediated gene delivery of two constructs containing 
complementary halves of a fluorescent protein linked to human α-Syn. This approach 
enables the study of α-Syn oligomers formation and transport in neurons and neuronal 
pathways. A similar approach was employed in a recent study [122]. 
AAV-mediated α-Syn delivery to the, motor cortex, substantia nigra or striatum  of 
Sprague Dawley rats  was performed and incubated for a period of 9 weeks (CX) or 12 
weeks (SN and ST), respectively. In the CX group, we performed a sciatic nerve crush 
9 weeks after viral injection to assess possible trans-synaptic transfer of α-Syn. In the 
SN and ST groups we performed behaviour tests at 4, 8 and 12 weeks after viral 
injection to examine the functional impacts of α-Syn expression in the brain. Then, 
histological analysis was conducted to validate the detection of α-Syn oligomers. 
Venus fluorescence was detected in the three injection areas, which demonstrate the 
direct delivery and expression of 2 viruses resulting from an in vivo α-Syn oligomer 
formation. Control animals injected with Venus alone exhibited stronger fluorescence 
than V1S+SV2 injected animals, as expected, given that in the V1S+SV2 injected 
animals not all the halves injected come together and reconstitute the fluorescence.  
Regarding the CX group, injected in the motor cortex, α-Syn oligomers were found 
throughout the corticospinal tract, from the place of injection until the thoracic part of 
the spinal cord indicating the oligomers transport throughout this neuronal pathway.  
Interestingly, we were able to detect the pathological-linked form of α-Syn, pS129, 
which means our model presents signs of pathology. However, IHC analysis of sciatic 
nerves did not reveal presence of human α-Syn. The motor cortex area is divided in 
several areas, and each one of these sub-areas is responsible for the motor control of 
specific parts of the body. In order to be able to detect human α-Syn near the site of 
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the crush in the sciatic nerve, the injection of the AAV vector would have to target 
specifically the motor cortex area responsible for the control of the hind limbs. In our 
case this motor cortex area was most probably not targeted, and that could explain why 
we could not detect human α-Syn near the site of the crush in the sciatic nerve. 
In all the three groups of the AAV-injected animals (CX, SN and ST), we detected 
presence of α-Syn oligomers in neurites and neuronal cell bodies. We were also able 
to detect great amounts of pSer129 in the cell bodies and neurites, linking this model to 
the pathology of PD, since pSer129 is known to have a role in α-Syn aggregation and 
to be present in LB of PD patients. 
Overexpression of α-Syn in cells has been shown to lead to a significantly reduced TH 
activity and DA synthesis [140, 141]. Quantification of TH-immunopositive neurons in 
the substantia nigra of SN group revealed no statistical differences, in agreement with 
the negative results from the motor behaviour tasks but contrary to previous studies 
[118-122, 151]. This could be due to differences in the virus titer or even in the time-
point.  However, the V1S+SV2 group of SN group, at 4 weeks showed impairment in 
the limb controlled by the side of injection in the stepping task. In the animals injected 
with the V1S+SV2 constructs the TH levels in the striatum, presented a tendency of 
decrease, however this did not reach statistical significance. The ST group revealed no 
statistical differences in the behaviour tasks as well as in the striatal fiber density, 
revealing still interestingly a tendency of increase in the TH levels in the striatum in the 
V1S+SV2 injected animals compared to the Venus-injected animals. The SN and ST 
groups had respectively 23 and 17 animals, however during the microscopy analysis of 
the place of injection, only the animals that had a precise targeting and a good 
expression of Venus fluorescence were chosen for the behavioural analysis and for the 
TH analysis. This process decreased significantly the number of animals. In the future, 
and in order to have more reliable results it would be valuable to have a bigger set of 
animals.   
Degeneration to axons and synapses in the striatum has been shown to 
precede the loss of DA neurons in the substantia nigra both in PD patients and in 
animal models of PD [152]. Evidences from rodent models of PD indicate that 
degeneration of the neurons starts in the axons, and not in the cell body. In a mouse 
model of PD dopaminergic presynaptic terminals of the striatum appeared reduced 
before cell body loss [153]. In our model we observed beaded axons in the striatum of 
rats of SN group injected with the V1S+SV2 construct, which is a sign of dystrophic 
axons consistent with reported in viral vector models [119, 122]. Moreover, animals 
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from the same group injected with the V1S+SV2 construct presented a trend of 
decrease in the TH levels of striatum, but no difference in the TH+ cells of substantia 
nigra, concordant with the hypothesis that neuronal degeneration starts in the axons. 
We might need a later time-point in order to see some cell loss or a higher virus titer in 
order to obtain a more severe phenotype; however our main goal was to visualize the 
pattern and transport of α-Syn oligomers, and the increase of virus titer is a risky 
approach since we do not want to overload the system with viral particles and cause 
severe degeneration.  
In a recent study, where rats were injected with AAV carrying α-Syn targeting the 
substantia nigra [122], the authors report TH+ cell loss in the substantia nigra of 
animals injected with V1S+SV2 as well as a reduction in TH+ levels  and presence of 
neuroinflammation in the striatum. Our results contrast with this study, but the apparent 
differences in the experimental design between the studies could account for the 
different results. Namely, the AAV serotype, depending on the main goal of the study, 
different AAV serotypes can be chosen according to their pattern of spread and 
effectivity. In our study AAV vectors pseudotyped with a serotype 6 capsid were 
chosen because of their high tropism for nigral dopaminergic neurons [154-156], while 
in the study by Dimant et al. the AAV used was the AAV serotype 8. The AAV8 is 
known to be more efficient for widespread gene deliver [157], but it is also neurotoxic to 
dopamine neurons in the substantia nigra at higher vector doses [158]. The difference 
in the serotype of the AAV used could then explain why using the same kind of 
approach, these reported results present neuronal cell loss while ours do not. Another 
factor that can contribute to a difference in the results is the titer of the virus/total viral 
load per animal; while in our model we used equal viral load for V1S+ SV2 and for 
Venus (1,25*1013 gc/ml) control virus, the other group used a different titre for 
V1S+VS2 (8,3*10
12
 gc/ml + 8,7*10
12
 gc/ml) and for Venus (1*10
12
 gc/ml). In future 
studies, in order to obtain phenotype, it would be interesting to increase the titre of the 
virus. However, as said before, this approach needs to be pondered since an increase 
in the titre of the virus could lead to an overload of the system, and in that case it would 
be difficult to resolve if the phenotype was due to the α-Syn oligomerization or due to 
the excess of virus particles. 
Since there is still an ongoing discussion about the fluorescence properties of 
the separate halves of the fluorescence protein [123, 124, 159] it would also be 
interesting and valuable in the future to have more controls. The two halves of the 
Venus alone could be separately injected in the same animal (to study if or how the two 
halves interact without being linked to another protein) or in different animals (in order 
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to understand better the fluorescent properties of the separate halves) and the two 
halves of the construct (V1S and SV2) could be separately injected in different animals 
(in roder to study he fluorescent properties of the constructs).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.:4.1 - Ideal controls. In an optimal  s tudy there should exis t 6 different controls.  The two halves of the 
Venus  alone could be separately injected in the same animal  (VenusN + VenusC) or in different animals 
(VenusN or VenusC) and the two halves  of the construct (V1S and SV2) could be separately injected in different 
animals . Besides those, i t’s important to inject Venus  alone. 
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Chapter 5. Conclusion 
Viral vector gene delivery has shown great promise in development of novel 
models replicating human disease conditions in animals. Using this technique we have 
created a novel animal model, based on over-expression of human α-Syn, which 
replicates the α-Syn aggregation and pathology seen in PD patients and furthermore it 
allows the detection of α-Syn oligomers in vivo. This study has for the first time shown 
that AAV6 delievery of α-Syn linked to a fluorescence protein in the motor cortex, 
striatum and substantia nigra is a good approach to study the pathology propagation. 
The pathology in this model was present as the phosphorylated form of α-Syn. 
Therefore, this rat model could become very useful for the study of the spreading of the 
disease and even for the study of therapies that could prevent this process. Although 
we used human wild-type α-Syn in our study, the gene delivery approach described 
here may be used to investigate other, mutated forms of α-Syn. Taken together, this 
model exhibiting α-Syn over-expression localized to motor cortex, striatum and 
substantia nigra provides significant advantages over current models for evaluating the 
oligomers formation and spreading as well as its effect on the pathology mechanisms 
observed in PD. Despite the results of the present work, it is still necessary to perform 
additional studies in order to optimize the viral injection and titre of the virus, and also 
have a bigger set of animals. It would be also interesting to perform a viral injection of 
the V1S and SV2 separately in distinct but connected regions of the brain (striatum and 
substantia nigra) in order to see if the two halves meet at some point, and if so, where.  
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